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abstract
PURPOSE Effective treatment options are limited for patients with acute myeloid leukemia (AML) who cannot
tolerate intensive chemotherapy. An international phase Ib/II study evaluated the safety and preliminary efficacy
of venetoclax, a selective B-cell leukemia/lymphoma-2 inhibitor, together with low-dose cytarabine (LDAC) in
older adults with AML.
PATIENTS AND METHODS Adults 60 years or older with previously untreated AML ineligible for intensive
chemotherapy were enrolled. Prior treatment of myelodysplastic syndrome, including hypomethylating agents
(HMA), was permitted. Eighty-two patients were treated at the recommended phase II dose: venetoclax 600 mg
per day orally in 28-day cycles, with LDAC (20mg/m2 per day) administered subcutaneously on days 1 to 10. Key
end points were tolerability, safety, response rates, duration of response (DOR), and overall survival (OS).
RESULTS Median age was 74 years (range, 63 to 90 years), 49% had secondary AML, 29% had prior HMA
treatment, and 32% had poor-risk cytogenetic features. Common grade 3 or greater adverse events were febrile
neutropenia (42%), thrombocytopenia (38%), and WBC count decreased (34%). Early (30-day) mortality was
6%. Fifty-four percent achieved complete remission (CR)/CR with incomplete blood count recovery (median
time to first response, 1.4 months). The median OS was 10.1 months (95% CI, 5.7 to 14.2), and median DOR
was 8.1 months (95% CI, 5.3 to 14.9 months). Among patients without prior HMA exposure, CR/CR with
incomplete blood count recovery was achieved in 62%, median DOR was 14.8 months (95% CI, 5.5 months to
not reached), and median OS was 13.5 months (95% CI, 7.0 to 18.4 months).
CONCLUSION Venetoclax plus LDAC has a manageable safety profile, producing rapid and durable remissions in
older adults with AML ineligible for intensive chemotherapy. High remission rate and low early mortality
combined with rapid and durable remission make venetoclax and LDAC an attractive and novel treatment for
older adults not suitable for intensive chemotherapy.
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INTRODUCTION
The median age at diagnosis of acute myeloid leu-
kemia (AML) is 68 years. Older adults are often in-
eligible for intensive chemotherapy and thus have
limited effective treatment options.1,2 Less-intensive
approaches to treatment, such as low-dose cytarabine
(LDAC), are associated with poor response rates (11%
to 19%) and median survival times (, 6 months).3-5
Similarly, initial treatment with azacitidine, decitabine,
or gemtuzumab ozogamicin result in complete re-
mission (CR) plus CR with incomplete blood count
recovery (CRi) rates of less than 30%.5-7 In part be-
cause of limited expectation of success, many older
patients do not receive leukemia therapy.8 These
factors underscore the high unmet need for more-
effective and less-toxic treatment options for older
adults with AML, particularly those who are ineligible
for intensive chemotherapy.
B-cell leukemia/lymphoma-2 (BCL-2) family mem-
bers, including BCL-2, BCL-XL, and MCL1, promote
cell survival by binding and sequestering pro-apoptotic
proteins in cancer cells. BCL-2 has been shown to
mediate chemoresistance and enhance survival of
leukemic blast and progenitor cells.9,10 Venetoclax, a
selective, potent, orally bioavailable small-molecule
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combination with other agents in several hematologic
malignancies.11-16 A phase II study reported an overall
response rate (ORR) of 19% with venetoclax monotherapy
in heavily pretreated patients with AML.17 Resistance to
venetoclax monotherapy may be mediated by other pro-
survival proteins, such as MCL1, that sequester endogenous
BCL-2 homology domain 3-only proteins (eg, Bim) released
by venetoclax on BCL-2 binding. Several drugs—including
anthracyclines, hypomethylating agents (HMAs), and
cytarabine—have demonstrated the ability to down-regulate
MCL1 expression and act synergistically with venetoclax
against AML cells in preclinical studies.18-20 As proof of
concept, a 61% CR/CRi rate was reported for venetoclax
combined with HMAs (ie, azacitidine or decitabine) in
treatment-naive older adults with AML,21 exceeding pre-
viously reported response rates for HMAs alone.5,7 Here, a
phase Ib/II study was conducted to determine the safety and
preliminary efficacy of venetoclax in combination with LDAC




Patients age 60 years or older with previously untreated
AML and ineligible for intensive chemotherapy were en-
rolled (Data Supplement). Patients with secondary AML or
prior treatment with HMAs for myelodysplastic syndrome
(MDS) were permitted. Exclusion criteria included prior
therapy for AML or any previous use of cytarabine for any
indication (more details in the Treatment section). Local
ethics committee approval was obtained, and patients
provided written informed consent. The study was con-
ducted in accordance with the International Conference on
Harmonization, Good Clinical Practice guidelines, and the
Declaration of Helsinki.
Study Design
This open-label, multicenter, multinational phase Ib/II
study (ClinicalTrials.gov identifier: NCT02287233) en-
rolled patients between January 2015 and May 2017. Data
cutoff for efficacy in this analysis was November 8, 2017;
cutoff for safety was January 30, 2018. Primary objectives
in the dose-escalation phase were to assess safety, phar-
macokinetics (PK), maximum tolerated dose, and recom-
mended phase II dose of venetoclax combined with LDAC.
In dose expansion, the primary objectives were to obtain
preliminary estimates of efficacy: ORR, including CR, CRi,
and partial remission (PR); duration of response (DOR);
and safety of the combination at the recommended phase II
dose.22 Exploratory objectives were to identify biomarkers of
efficacy and resistance.
Treatment
Patients were hospitalized and tumor lysis syndrome (TLS)
prophylaxis was initiated at least 24 hours before the first
dose of venetoclax and continued during a ramp-up period
until the target venetoclax dose was reached. Venetoclax
was administered orally, once daily, after food. Venetoclax
dosing began at 50 or 100 mg and increased over 4 to
5 days to the target venetoclax dose; dosing was continued
through day 28 of each cycle. In subsequent 28-day cycles,
venetoclax was commenced at the target dose. LDAC
(20 mg/m2) was administered by subcutaneous injection
once daily, on days 1 to 10. At the completion of a 28-day
cycle, if bone marrow blasts were less than 5%, venetoclax
dosing was interrupted if needed to promote recovery of
neutrophils and platelets. Patients could start the next cycle
of therapy when the neutrophil count recovered to least
0.5 3 109/L and the platelet count to at least 25 3 109/L.
Once morphologic evidence of leukemia was cleared,
granulocyte colony stimulating factor was permitted at in-
vestigator’s discretion. Patients could continue receiving
treatment until disease progression or until discontinuation
criteria were met (Data Supplement).
Because venetoclax is a Cytochrome P450 (CYP3A) sub-
strate, patients receiving CYP3A inhibitors (CYP3A4i) had their
venetoclax dose reduced by approximately 50% for moderate
CYP3A inhibitors and approximately 75% to 90% for strong
inhibitors.23 If a patient was on multiple inhibitors, venetoclax
dose adjustment was based on the strongest CYP3Ai.
Study Assessments
Safety. Adverse events (AEs) were graded according to the
National Cancer Institute Common Terminology Criteria for
Adverse Events Version 4.03.24 Dose-limiting toxicities
(DLTs) were determined during cycle 1 of the dose-
escalation phase and defined as grade 4 toxicity, exclud-
ing AEs commonly caused by AML (eg, neutropenia, fever).
Hematologic DLT was defined as failure of platelet recovery
to 25 3 109/L or greater and neutrophils to 0.5 3 109/L or
greater within 14 days of the last dose of venetoclax in the
absence of residual AML. Clinical and laboratory TLS were
considered as previously defined.25
Efficacy. Bone marrow assessments were performed at
screening, after cycles 1 and 3, and then every three cycles
until two consecutive samples confirmed CR. Additional
bone marrow studies were performed if there was clinical
suspicion of recurrence and at final visit. Clinical responses
were defined according to International Working Group
response criteria for AML (Data Supplement).22
PK and exploratory biomarkers. Pharmacokinetic assess-
ment is described in the Data Supplement. Biomarkers that
may be predictive of venetoclax activity and response were
assessed during the trial (Data Supplement). Clinical out-
come was correlated with theWHO2008 classification26 and
cytogenetic and molecular markers, including the
chromatin-spliceosome, TP53-aneuploidy, and IDH R172
mutation subgroups, as recently proposed.27 Karyotypic
abnormalities were classified using site-reported results, and
centrally reported next-generation sequencing data were
used to supplement molecular mutation results.
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Statistical Analyses
All baseline summary statistics and analyses were based on
patient characteristics obtained before initiation of ven-
etoclax or LDAC. The safety population included patients
who received at least one dose of venetoclax; the DLT-
evaluable population included patients who received at
least 80% of planned cycle 1 doses during dose-escalation
phase. Further details of statistical analyses are contained
in the Data Supplement. For the phase II portion, it was
initially planned to enroll 25 patients at the recommended
phase II dose to enable a 95% CI for estimation of ORR with
margin of error not exceeding plus or minus 25%. The
study was later amended to enroll an additional 28 patients
to provide further precision regarding the observed re-
sponse rate estimates, and another 21 patients were en-
rolled to evaluate patients allowed to receive concomitant
strong CYP3Ai if indicated.
RESULTS
All patients enrolled at least 6 months before this analysis.
At the time of analysis, the median treatment duration was
4.2 months (range, 0.2 to 29 months), and the median
number of cycles of therapy was five. The median number
of cycles of LDAC delivered to patients who achieved CR
was seven (range, two to 30), and five (range, one to 16) for
patients achieving CRi. Seven patients (9%) remained in
the study therapy at of time of analysis.
Patient Demographics and Clinical Characteristics
Eighty-two patients were enrolled to a 600 mg venetoclax
cohort and received at least one dose of venetoclax.
Baseline demographics and clinical characteristics for the
600 mg venetoclax cohort are shown in Table 1. The
median age was 74 years (range, 63 to 90 years). Forty-
nine percent of patients had secondary AML, and 50% had
concomitant CYP3A inhibitor use. Baseline mutations in
TP53, FLT3, IDH1/2, and NPM1 were detected in 14%,
23%, 25%, and 13% of patients, respectively.
DLT and Maximum Tolerated Dose
No DLTs were observed in the 600 mg venetoclax cohort
during the dose-escalation phase of the study. Of the six
patients in the 600 mg dose escalation cohort who pro-
ceeded to subsequent cycles, only one patient required
dose interruption between cycles 1 and 2, because of
thrombocytopenia without residual morphologic AML. At
the 800 mg dose level (n = 10), most patients who pro-
ceeded to subsequent cycles needed dose interruption
between cycles 1 and 2 to permit count recovery, and one
patient experienced a hematologic dose-limiting toxicity
(grade 4 thrombocytopenia lasting more than 42 days
without evidence of residual leukemia in a patient with AML
secondary to myeloproliferative neoplasm). Therefore, the
recommended phase II dose was determined to be ven-
etoclax 600 mg when combined with LDAC.
Safety Profile
A summary of treatment-emergent AEs for the venetoclax
600 mg cohort is shown in Table 2; further breakdown is
available in the Data Supplement. Consistent with expec-
tations for AML, the common grade 3 or 4 AEs, irrespective
of cause, were frequently hematologic and included febrile
neutropenia (42%), thrombocytopenia (38%), neutropenia
(27%), and anemia (27%). The most common non-
hematologic AEs of any grade or cause were nausea (70%),
diarrhea (49%), hypokalemia (48%), and fatigue (43%).
Serious AEs other than AML progression, occurring in at
least 5% of patients, were anemia (31%), febrile neu-
tropenia (27%), pneumonia (10%), and sepsis (7%).
Forty-five (55%) patients had venetoclax dose interruptions
due to AEs, most commonly between subsequent 28-day
cycles (due to delayed neutrophil and platelet recovery in eight
and 10 patients, respectively). Dose reductions were neces-
sary in six patients (7%), the majority due to thrombocyto-
penia. Reduced duration of venetoclax administration to 21
and 14 days occurred in 25 patients (30%) and 14 patients
(17%), respectively. Laboratory-defined TLS was reported in
two patients (elevations of potassium and phosphorus in one
patient and elevations of uric acid and phosphorus in the
other), although both were able to complete the venetoclax
ramp-up to the intended dose. No clinical TLS was reported.
The 30-day mortality rate was 6% (n = 5).
Efficacy
In phase I and II, a total of 82 patients were enrolled to the
venetoclax 600 mg dose level. The CR/CRi rate was 54%
(95% CI, 42% to 65%); CR was achieved in 26% of pa-
tients, and CRi in 28% (Fig 1). Median time to first CR/CRi
was 1.4 months (range, 0.8 to 14.9 months). Patients with
de novo AML and intermediate-risk cytogenetic features
and without prior HMA exposure had the highest rates of
CR/CRi: 71%, 63%, and 62%, respectively (Fig 1). A
complete breakdown of responses by baseline patient
features is shown in the Data Supplement. Among patients
achieving CR/CRi after venetoclax plus LDAC, the median
duration of remission was 8.1 months (95% CI, 5.3 to
14.9 months; Fig 2A). The median OS for all patients was
10.1 months (95% CI, 5.7 to 14.2 months; Fig 2B). Ob-
served survival for the study population was better for
patients achieving CR, CRi, or both (Fig 2C). The 12-month
estimated survival rate for those who achieved CR, CRi, CR/
CRi, or no response was 100%, 49%, 73%, and 5%, re-
spectively (Fig 2C, arrows). Patients without prior HMA
exposure had a longer median OS (13.5 months; 95% CI,
7.0 to 18.4 months) than patients with AML previously
exposed to prior HMA (4.1 months; 95% CI, 2.9 to
10.1 months; Fig 2D).
Most patients who achieved remission became transfu-
sion independent. Among patients treated with venetoclax
in combination with LDAC, 46% (38 of 82) achieved
independence from both RBC and platelet transfusion.
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Forty-eight percent (39 of 82) achieved RBC transfusion in-
dependence, and 60% (49 of 82) achieved platelet transfusion
independence. Among the patients who were dependent on
transfusions before enrollment, 43% (23 of 53) of those de-
pendent on RBC transfusions and 65% (15 of 23) of those
dependent on platelet transfusions became transfusion in-
dependent while in the study. The time required for platelet
($ 503 109/L) and neutrophil ($ 0.53 109/L) recovery was
assessed among patients who achieved CR/CRi (Data Sup-
plement). The median time to platelet recovery was 28 days,
with 90% or more reaching this threshold by day 53. The
median time to absolute neutrophil count recovery was
32 days, with 90% recovered by day 64.
PK
Venetoclax and cytarabine PK parameters are shown in the
Data Supplement. PK concentration-time profiles of ven-
etoclax and cytarabine are shown in the Data Supplement.
These studies showed no impact on drug exposures of
combining venetoclax with cytarabine, thus indicating an
absence of substantial PK interaction.
Key AML Genetic Mutations and Clinical Response
There are several key genetic mutations that have been
identified in driving the progression, prognosis, and out-
come in AML, including mutations in TP53, FLT3, IDH1/2,
and NPM1; a genomic classification system for AML has
been recently developed, largely around these molecular
drivers (among others).27,28 Patients with somatic muta-
tions in NPM1 or IDH1/2 had higher than average CR/CRi
rates (89% and 72%, respectively), whereas those with
TP53 or FLT3mutations had lower CR/CRi rates (30% and
44%, respectively; Data Supplement).
DISCUSSION
Optimizing treatment selection for older adults with AML
remains challenging. Higher incidence of treatment-related
complications is expected from intensive chemotherapy
because poor performance status and comorbidities are
more prevalent in the elderly.29 Poor outcomes with in-
tensive chemotherapy are also typical for older patients with
poor-risk cytogenetics, monosomal karyotype, secondary
AML, or MDS after failure of prior HMA therapy.30-32 For
patients older than 65 years receiving intensive chemo-
therapy, reported remission rates range between 45% and
57% and median OS between 5 and 12 months.33,34 For
patients between 60 and 75 years of age and previously
treatedwith anHMA, CR/CRi rates are only 28% for intensive
7 plus 3 chemotherapy and 37% for patients receiving li-
posomal daunorubicin and cytarabine (CPX-351).35 Ac-
cordingly, many physicians and patients elect a low-intensity
approach to therapy or no active treatment at all.36
Low-intensity therapies, such as LDAC monotherapy, have
historically been administered with palliative intent, with
CR/CRi rates of 11% to 19% and median OS of approxi-
mately 5.5 months.4,31 Therefore, the observed CR/CRi rate
of 54% and 10.1-month median survival for patients
treated with venetoclax plus LDAC seems favorable. Among
patients older than 75 years, the rate of CR/CRi remained
60%, with median OS of 14.9 months. Importantly, the
higher clinical response rate was achieved without an in-
crease in early mortality: the 30-day mortality rate was 6%
in the first month after LDAC plus venetoclax treatment,
compared with 8% to 13% with LDAC alone from literature
reports.4,31 This raises the possibility of also evaluating
venetoclax combined with low-intensity therapy in younger
and/or more fit patients with AML, with the goal of sparing
patients the greater toxicity generally observed with in-
tensive chemotherapy.
TABLE 1. Patient Demographics and Clinical Characteristics
Characteristic Venetoclax 600 mg + LDAC (n = 82)
Age, years, median (range) 74 (63-90)
$ 65 80 (98)
$ 75 40 (49)
Male 53 (65)
AML type







Bone marrow blast count
, 30% 27 (33)
$ 30% to , 50% 18 (22)
$ 50% 36 (44)
Antecedent hematologic disorder 40 (49)










CYP3A inhibitor use 41 (50)
NOTE. Data are presented as No. (%) unless otherwise noted.
Abbreviations: AML, acute myeloid leukemia; CYP3A, Cytochrome P450; ECOG,
Eastern Cooperative Oncology Group; HMA, hypomethylating agent; LDAC, low-
dose cytarabine.
*Mutation data missing for 11 patients; percentage calculated based on the
number of patients with data (n = 71).
1280 © 2019 by American Society of Clinical Oncology Volume 37, Issue 15
Wei et al
Downloaded from ascopubs.org by UNIVERSITY OF TEXAS AT AUSTIN on October 17, 2019 from 129.127.079.196
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
The outcomes achieved with venetoclax plus LDAC also
compare favorably with those obtained during recent
studies of HMA monotherapy in older patients with AML:
decitabine resulted in CR/CRi of 25.6% and median OS
of 7.7 months in older adults with newly diagnosed AML5;
azacitidine achieved CR/CRi of 27.8% and median OS
of 10.4 months in another phase III study, which in-
cluded patients either eligible or ineligible for intensive
chemotherapy.7 Importantly, both historical studies ex-
cluded patients who had received prior HMA for MDS,
whereas in the current study, 29% of patients had
previously received an HMA. For HMA-naive participants
in the current study, the CR/CRi rate was 62%, with a
median duration of response 14.8 months and median
OS of 13.5 months.
Historical rates of CR/CRi for patients treated with LDAC,
azacitidine, or decitabine monotherapy are between 11%
and 26%,5,37 with moderate difference in CR rates ob-
served between patients with intermediate-risk versus poor-
risk cytogenetics (reported differences between 3% and
13%).38,39 In the current study, rates of CR/CRi were 63%
and 42% for patients with intermediate-risk and poor-risk
cytogenetics, respectively. Among patients with mutant
NPM1, the CR/CRi rate was 89% (eight of nine), which
included two patients with coexisting FLT3 and IDH1/2
mutations and three additional patients with either mutant
FLT3 or IDH1/2; all eight patients remain alive at more than
1 year. Although larger validation studies are needed, these
preliminary observations suggest that such patients may be
especially responsive to venetoclax plus LDAC therapy.
Responses to venetoclax monotherapy have been previously
reported in patients with IDH1 or IDH2 mutations.40 In the
current study, venetoclax plus LDAC resulted in a CR/CRi rate
of 72% (13 of 18) and median OS of 19.4 months among
patients with IDH1/2-mutant AML. Therefore, venetoclax plus
LDAC may also represent a useful treatment strategy for
patients with treatment-naive IDH1/2-mutant AML who are
ineligible for intensive chemotherapy; further integration of
IDH1/2 inhibitors into this regimen for patients with persistent
IDH-positive disease may be an objective for future clinical
trials. Among patients with TP53mutation or poor cytogenetic
risk, the CR/CRi rate with LDAC and venetoclax was 30%
(three of 10) or 42% (11 of 26), respectively, indicating that
these historically identified features of poor prognosis remain
relevant for this combination.
Venetoclax plus LDAC was associated with rapid achieve-
ment of CR/CRi, with median time to first response of
1.4 months, compared with 3.1 months for LDAC alone4 and
3.5 to 4.1 months with HMA therapies.37 However, clinical
vigilance and robust supportive care measures are neces-
sary until blast clearance and hematologic recovery are
achieved. At the onset of this trial, antifungal prophylaxis
with azole antifungals (CYP3A inhibitors) was prohibited
because of the potential of increasing venetoclax exposure.41
However, separate pharmacokinetic studies reported that
TABLE 2. Summary of Treatment-Emergent AEs
AE Venetoclax 600 mg + LDAC (n = 82)
Any AE 82 (100)
AE with grade $ 3
Febrile neutropenia 34 (42)
Thrombocytopenia 31 (38)
WBC count decreased 28 (34)
Anemia 22 (27)
Neutropenia 22 (27)
Platelet count decreased 20 (24)
Lymphocyte count decreased 15 (18)








Febrile neutropenia 22 (27)
Pneumonia 8 (10)
AML progression 7 (9)
Sepsis 6 (7)
NOTE. Data are presented as No. (%). Adverse events (AEs) were listed if they were
reported for at least 10% of patients with grade 3 or higher or at least 5% of patients
with serious AEs.
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FIG 1. Complete remission (CR)/CR with incomplete blood count
recovery (CRi) rates by patient subgroups. The graph shows the rates
of CR and CRi in all patients, as well as key patient subgroups sorted
by baseline characteristics. The numbers in the bars represent the
percentage of patients with a given response, and the black number at
the top of each bar is the total CR/CRi percentage in a given subgroup.
Partial remissions are not shown, because only one patient had a partial
remission. AML, acutemyeloid leukemia; HMA, hypomethylating agent;
intrmed, intermediate.
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venetoclax can be administered, with appropriate dose
reductions, to patients with AML using concomitant
moderate or strong CYP3A inhibitors (such as the anti-
fungal azoles voriconazole or posaconazole).23 Conse-
quently, a cohort was added to prospectively evaluate the
impact of allowing CYP3A inhibitors when medically re-
quired. As such, 50% of the patients enrolled and treated
had concomitant CYP3A inhibitor use; no increase in
adverse events related to potential CYP3A inhibitor in-
teraction was observed.
Because patients with prior HMA exposure were included in
the current study, it is difficult to directly compare efficacy
between the current study and historical results. Clinical trials
of low-intensity therapies have historically excluded patients
who received prior treatment with HMAs, and such patients
have an especially poor prognosis. In the current study, nearly
one-third (29%) of patients had prior HMA exposure. The CR/
CRi rate for those patients with prior HMA exposure was 33%,
comparable to rates reported for intensive chemotherapy or
CPX-351 for patients experiencing disease progression after
prior HMA therapy for antecedent conditions. Among patients
without prior HMA treatment, the CR/CRi rate for venetoclax
plus LDACwas 62%, which is similar to the reported CR/CRi
rate of 67% in a recently published study that combined
venetoclax with HMAs for patients with AML.21 As such,
both venetoclax studies, in combination with LDAC or
HMAs, support a role for venetoclax as an integral com-
ponent of standard therapy, especially in older adults with
AML. International randomized studies are currently un-
derway for venetoclax or placebo combined with either
LDAC (ClinicalTrials.gov identifier: NCT03069352) or aza-
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No. at risk: No. at risk:
No. at risk: No. at risk:
FIG 2. Overall survival and duration of response. Kaplan-Meier curves showing (A) duration of remission for patients who had complete remission (CR)/CR
with incomplete blood count recovery (CRi); (B) overall survival of all patients; (C) overall survival broken down by the patients’ best response; (D) overall
survival by prior hypomethylating agent (HMA) exposure. NOTE: Numbers in parentheses are 95% CIs. DS, discontinued prior to assessment; LDAC, low-
dose cytarabine; MLFS, morphologic leukemia–free state; NA, not available; NR, not reached; PD, progressive disease; PR, partial remission; RD, resistant
disease; Ven, venetoclax.
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In conclusion, the combination of venetoclax and LDAC is
tolerable and associated with high rates of remission in
patients with previously untreated AML who are ineligible
for intensive chemotherapy. The high remission rate, low
early mortality, rapid induction of remission, and durable
length of remission make the combination with venetoclax
an attractive and novel treatment option for older adults not
suitable for intensive chemotherapy.
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